<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974595</url>
  </required_header>
  <id_info>
    <org_study_id>170016</org_study_id>
    <secondary_id>17-I-0016</secondary_id>
    <nct_id>NCT02974595</nct_id>
  </id_info>
  <brief_title>Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)</brief_title>
  <official_title>Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Some diseases cause chronic inflammation with intermittent flares in the body. These are&#xD;
      called autoinflammatory diseases. They can cause fevers, rashes, ulcers, and other problems.&#xD;
      Researchers want to learn more about the causes and effects of these diseases. They hope this&#xD;
      will improve how the disease is managed in the future.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To understand the underlying immune dysregulation&#xD;
&#xD;
      To identify the genetic cause&#xD;
&#xD;
      To translate our findings into novel treatments that improve patients disease outcomes&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's Disease, and with&#xD;
      other yet undifferentiated autoinflammatory diseases.&#xD;
&#xD;
      Unaffected relatives of participants with a known or undifferentiated autoinflammatory&#xD;
      disease&#xD;
&#xD;
      Healthy adult volunteers at least 18 years of age&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with blood sample and medical history. They may provide copies&#xD;
      of their medical records.&#xD;
&#xD;
      Enrolled participants will be evaluated at the NIH for 2-5 days. All participants will have a&#xD;
      detailed medical history, physical exam, blood tests, and other evaluations depending on the&#xD;
      extent of their autoinflammatory disease.&#xD;
&#xD;
      Participants may also expect the following assessments:&#xD;
&#xD;
        1. Clinical tests that help assess organ damage and function such as hearing, vision,&#xD;
           memory, and learning tests.&#xD;
&#xD;
        2. Imaging studies to characterize organ involvement of the inflammatory disease including:&#xD;
           X-rays, CT scans, special MRIs, and bone scans.&#xD;
&#xD;
        3. Laboratory evaluations including clinical markers of disease activity, research samples&#xD;
           for genetic studies, blood samples for cytokine/biomarker assessment, and gene&#xD;
           expression profiling.&#xD;
&#xD;
        4. Questionnaires to assess disease activity and quality of life.&#xD;
&#xD;
        5. If indicated, other procedures may be administered that include: a lumbar puncture if&#xD;
           CNS inflammation is suspected, a skin biopsy if skin inflammation is present, and/or&#xD;
           gastrointestinal and pulmonary procedures if they are clinically indicated.&#xD;
&#xD;
      Participants may return for a single follow-up visit or for long-term follow-up visits&#xD;
      depending on their disease and willingness to return. Long-term follow-up may occur for up to&#xD;
      15 years on this protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoinflammatory diseases are a group of immune dysregulatory diseases that are characterized&#xD;
      by recurrent episodes of systemic as well as organ-specific inflammation that can involve the&#xD;
      skin, eyes, joints, bones, muscles, lungs, serosal surfaces, inner ear, brain, and other&#xD;
      organs. The prominent role of IL-1 in the pathogenesis of these disorders first became&#xD;
      evident through the discovery of mutations in the gene NLRP3 and IL1RN. Since then, we have&#xD;
      identified additional mutations that cause autoinflammatory diseases, including mutations in&#xD;
      proteasome components and STING1 that suggest a role of increased type I IFN signaling as a&#xD;
      contributor to the disease pathogenesis of autoinflammatory diseases and in NLRC4 and CDC42&#xD;
      that suggest a role of IL-18 in some autoinflammatory diseases. In this natural history&#xD;
      study, we seek to comprehensively evaluate people with autoinflammatory diseases that include&#xD;
      clinical, genetic, immunologic, andendocrinologic characterizations. Other rare diseases not&#xD;
      mediated by IL-1, IL-18 or type I IFN and presumed to be autoinflammatory diseases with&#xD;
      unknown genetic causes may also be eligible under this protocol. In addition, we intend to&#xD;
      evaluate long-term outcomes and biomarkers over time in selected diseases. We plan to follow&#xD;
      most participants for the duration of this study (15 years). Relatives who do not have&#xD;
      autoinflammatory diseases as well as healthy volunteers will also be recruited to serve as&#xD;
      controls for biomarker, genetic, and other molecular analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2032</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2031</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study the pathogenesis of patients affected with autoinflammatory diseases, including their clinical, immunological, genetic and metabolic/endrocrinological characteristics.</measure>
    <time_frame>1-2 years, 3-5 years, 10 years</time_frame>
    <description>To study the pathogenesis of patients affected with autoinflammatory diseases, including their clinical, immunological, genetic and metabolic/endocrinological characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To collect long-term clinical and laboratory outcome parameters of the multiorgan inflammatory involvement and/or organ damage in patients with genetically defined or undifferentiated autoinflammatory (immune-dysregulatory) diseases.</measure>
    <time_frame>1-2 years, 3-5 years, 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical characteristics-disease manifestations and blood, body fluids, and tissue biomarkers during disease flares and quiescence</measure>
    <time_frame>1-2 years, 3-5 years, 10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>NOMID</condition>
  <condition>DIRA</condition>
  <condition>NLRC4-MAS</condition>
  <condition>SAVI</condition>
  <condition>CANDLE</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Participants age 0-99 will have a known autoinflammatory disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Unaffected relatives age 3-99 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Healthy Volunteers age 18-99 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population is quite diverse as affected participants are from all over the world.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA - AFFECTED PARTICIPANTS:&#xD;
&#xD;
               1. Be 2 to 99 years old for participants who will be seen at the NIH CC; be 0&#xD;
                  (newborn) to 99 years old for participants who participate remotely via a virtual&#xD;
                  protocol visit and will submit mail-in samples. Participants younger than 3 years&#xD;
                  will be seen in the outpatient clinic at the NIH CC if approved by the Pediatric&#xD;
&#xD;
                  Consult Service as per NIH CC policy and guidelines.&#xD;
&#xD;
               2. Is willing to allow storage of biological specimens for future use in medical&#xD;
                  research.&#xD;
&#xD;
               3. Is willing to allow genetic testing on collected biological samples.&#xD;
&#xD;
               4. Has a primary care or other physician who will manage all health conditions&#xD;
                  related or unrelated to the study objectives.&#xD;
&#xD;
               5. Fulfills one of the following criteria:&#xD;
&#xD;
                    -  Has a known disease-causing genetic mutation associated with NOMID/CAPS,&#xD;
                       DIRA, CANDLE, SAVI, or NLRC4-MAS.&#xD;
&#xD;
                    -  Has clinical signs or symptoms not explained by any other disorder (eg,&#xD;
                       infections, malignancies) and are consistent with a possible IL-1 mediated&#xD;
                       autoinflammatory disease. Participants must meet both of the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  Clinical characteristics strongly consistent with an IL-1 mediated&#xD;
                            autoinflammatory disease per the following criteria and at the&#xD;
                            discretion of the principal investigator (PI). Individuals must have a&#xD;
                            past or present history of one of the following to be considered for&#xD;
                            study enrollment:&#xD;
&#xD;
                              -  Recurrent fever that has gone undiagnosed after reasonable&#xD;
                                 attempts, and that is consistent with the conditions under study&#xD;
                                 in this protocol&#xD;
&#xD;
                              -  Neutrophilic urticaria, pustular dermatitis, erysipelas-like&#xD;
                                 erythema, or urticarial rash&#xD;
&#xD;
                              -  Epiphyseal and/or patella enlargement, periostitis, myalgias,&#xD;
                                 arthralgias, arthritis, or recurrent multifocal aseptic&#xD;
                                 osteomyelitis&#xD;
&#xD;
                              -  Sensorineural hearing loss&#xD;
&#xD;
                              -  Chronic aseptic meningitis or CNS vasculitis&#xD;
&#xD;
                              -  Conjunctivitis, episcleritis, uveitis, papilledema, pleuritis,&#xD;
                                 pericarditis, aseptic peritonitis, early onset enterocolitis,&#xD;
                                 hepatosplenomegaly, or lymphadenopathies&#xD;
&#xD;
                         -  Laboratory characteristics strongly consistent with an IL-1mediated&#xD;
                            autoinflammatory disease per the following criteria. Individuals must&#xD;
                            havepast or present history of evidence of systemic inflammation (eg,&#xD;
                            elevation of C-reactive protein [CRP] and/or erythrocyte sedimentation&#xD;
                            rate [ESR], anemia, thrombocytosis).&#xD;
&#xD;
                    -  Has clinical signs or symptoms not explained by any other disorder (eg,&#xD;
                       infections, malignancies) and are consistent with a possible IFN-mediated,&#xD;
                       autoinflammatory disease.1,36 Participants must meet both of the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  Clinical characteristics strongly consistent with an IFN-mediated&#xD;
                            autoinflammatory disease per the following criteria and at the&#xD;
                            discretion of the PI. Individuals must have a past or present history&#xD;
                            of one of the following to be considered for study enrollment:&#xD;
&#xD;
                              -  Recurrent fevers that has gone undiagnosed after reasonable&#xD;
                                 attempts, and that is consistent with the conditions under study&#xD;
                                 in this protocol&#xD;
&#xD;
                              -  Panniculitis, ischemic ulcerative skin lesions, chilblain lesions,&#xD;
                                 or livedo reticularis&#xD;
&#xD;
                              -  Lipodystrophy&#xD;
&#xD;
                              -  Myositis, arthralgias, arthritis, or joint contractures&#xD;
&#xD;
                              -  Basal ganglia calcifications or white matter CNS disease&#xD;
&#xD;
                              -  Interstitial lung disease, lung fibrosis, or pulmonary&#xD;
                                 hypertension&#xD;
&#xD;
                              -  Conjunctivitis, episcleritis, cortical blindness, glaucoma,&#xD;
                                 papilledema, or hepatosplenomegaly&#xD;
&#xD;
                              -  Laboratory characteristics strongly consistent with an&#xD;
                                 IFN-mediated autoinflammatory disease per the following criteria.&#xD;
                                 Individuals must have past or present history one or more of the&#xD;
                                 following to be considered for study enrollment:&#xD;
&#xD;
                              -  Evidence of systemic inflammation (eg, ESR or CRP)&#xD;
&#xD;
                              -  Cytopenias (eg. leukopenia, anemia, or thrombocytopenia)&#xD;
&#xD;
                              -  Dyslipidemia or insulin resistance&#xD;
&#xD;
                              -  Abnormal liver function test, creatinine kinase (CK), or LDH&#xD;
&#xD;
                    -  Has clinical signs or symptoms consistent with an undifferentiated&#xD;
                       autoinflammatory disease (including but not limited to dysregulation in&#xD;
                       other proinflammatory cytokines such as IL-17, TNF, IL-18, and others).&#xD;
                       Participants must meet one of the following criteria:&#xD;
&#xD;
                         -  Clinical characteristics strongly consistent with an undifferentiated&#xD;
                            autoinflammatory disease. Individuals must have a past or present&#xD;
                            history of one of the clinical and one of the laboratory&#xD;
                            characteristics mentioned above to be considered for study enrollment.&#xD;
&#xD;
                         -  Individuals with defined organ inflammation associated with past or&#xD;
                            current evidence of systemic inflammation.&#xD;
&#xD;
               6. Alternatively to #5, had been enrolled in the past as an affected participant on&#xD;
                  NIAMS study 03-AR-0173 and or had samples collected on 03-AR-0173.&#xD;
&#xD;
        INCLUSION CRITERIA - UNAFFECTED RELATIVES OF AFFECTED PARTICIPANTS:&#xD;
&#xD;
          1. Be 2 to 99 years old for participants who will be seen at the NIH CC; be 0 (newborn)&#xD;
             to 99 years old for participants who participate remotely via a virtual protocol visit&#xD;
             and will submit mail-in samples. Participants younger than 3 years will be seen in the&#xD;
             outpatient clinic at the NIH CC if approved by the Pediatric Consult Service as per&#xD;
             NIH CC policy and guidelines.)&#xD;
&#xD;
          2. Be related by blood to an affected participant.&#xD;
&#xD;
          3. Is willing to allow storage of biological samples for future use in medical research.&#xD;
&#xD;
          4. Is willing to allow genetic testing on collected biological samples.&#xD;
&#xD;
          5. Does not fulfill any of inclusion criterion #5 for affected participants.&#xD;
&#xD;
          6. Is able to provide informed consent.&#xD;
&#xD;
        INCLUSION CRITERIA - HEALTHY VOLUNTEERS:&#xD;
&#xD;
          1. Be at least 18 years old.&#xD;
&#xD;
          2. Not be related to an affected participant.&#xD;
&#xD;
          3. s willing to allow storage of biological samples for future use in medical research.&#xD;
&#xD;
          4. Is willing to allow genetic testing on collected biological samples.&#xD;
&#xD;
          5. Does not fulfill any of inclusion criterion #5 for affected participants.&#xD;
&#xD;
          6. Is able to provide informed consent.&#xD;
&#xD;
        PARTICIPANT EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Presence of conditions that, in the judgment of the investigator, may put the&#xD;
             participant at undue risk or make them unsuitable for participation in the study.&#xD;
&#xD;
          2. Oncological evaluation suggestive of lymphoma, leukemia or multiple myeloma, except&#xD;
             for participants with a known primary diagnosis of an autoinflammatory disease who&#xD;
             subsequently developed a malignancy. These patients will not be excluded from the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaela T Goldbach-Mansky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katsiaryna Uss</last_name>
    <phone>(240) 292-4709</phone>
    <email>kat.uss@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-I-0016.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006 Aug 10;355(6):581-92.</citation>
    <PMID>16899778</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee CC, Chen Y, Vera A, Zhang X, Goldbach-Mansky R, Zlotogorski A. Mutations in proteasome subunit Î² type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012 Mar;64(3):895-907. doi: 10.1002/art.33368.</citation>
    <PMID>21953331</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CR, DiMattia MA, Cowen EW, Gonzalez B, Palmer I, DiGiovanna JJ, Biancotto A, Kim H, Tsai WL, Trier AM, Huang Y, Stone DL, Hill S, Kim HJ, St Hilaire C, Gurprasad S, Plass N, Chapelle D, Horkayne-Szakaly I, Foell D, Barysenka A, Candotti F, Holland SM, Hughes JD, Mehmet H, Issekutz AC, Raffeld M, McElwee J, Fontana JR, Minniti CP, Moir S, Kastner DL, Gadina M, Steven AC, Wingfield PT, Brooks SR, Rosenzweig SD, Fleisher TA, Deng Z, Boehm M, Paller AS, Goldbach-Mansky R. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014 Aug 7;371(6):507-518. doi: 10.1056/NEJMoa1312625. Epub 2014 Jul 16.</citation>
    <PMID>25029335</PMID>
  </reference>
  <verification_date>July 26, 2021</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Study of pathogenesis of patients affected with autoinflammatory diseases</keyword>
  <keyword>This Includes the Clinical, Immunological , Genetic, and Metabolic Characteristi</keyword>
  <keyword>Collection of Clinical and Laboratory Outcome Data</keyword>
  <keyword>Evaluation of Characteristics/Disease Manifestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

